Over 5000 patient data will be used to identify image changes and patterns in liver cancer, helping physicians make better treatment decisions
Lucence Diagnostics, a genomic medicine company in Singapore focused on personalising cancer care, is developing AI algorithms to improve the diagnosis and treatment of liver cancer.
The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.
They will be working together with Olivier Gevaert, PhD, Assistant Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science at the Stanford University School of Medicine.
Liver cancer is the second leading cause of avoidable cancer deaths globally. The best chance of cure is surgery, and good characterisation of the extent and type of the disease is critical for surgical planning.
Imaging tests such as ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) play a crucial role in the visualisation of liver tumours.
Fusing imaging data with sequencing data that includes both cancer mutations and viral DNA will create a unique opportunity for AI-based approaches to advance liver cancer care.
This project will evaluate a dataset of over 5,000 patients to identify image changes and patterns that are linked to diagnostic and treatment outcomes in liver cancer.
Click here for the complete issue.